Clinical Research Directory
Browse clinical research sites, groups, and studies.
Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms
Sponsor: Tianjin Anding Hospital
Summary
"Negative" symptoms are a major challenge for people with schizophrenia (SZ) and are a key reason why they struggle with everyday functioning. While current medications work well for the "positive" symptoms (like hallucinations or delusions), they aren't very effective at improving these "negative" symptoms, which include things like a lack of motivation or emotion. This study plans to conduct a large, randomized, double-blind, placebo-controlled trial to see if a compound called berberine (BBR) can safely and effectively improve these negative symptoms in SZ. The investigators will also examine how BBR affects gut bacteria, their byproducts in stool, and levels of general inflammation in the body. By looking at these different biological markers before and after BBR treatment, the investigators aim to understand how BBR influences negative symptoms and identify its main targets for improvement. This could lead to new ways to treat negative symptoms in schizophrenia in the future.
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2023-09-26
Completion Date
2026-04-30
Last Updated
2026-01-27
Healthy Volunteers
No
Interventions
Berberine
Berberine 300 mg by mouth each dose# three times a day# plus any stable antipsychotic drug
Placebo
The placebo were matched to Berberine in shape, smell and colour and tablets were sealed in identical bottles
Locations (1)
Tianjin Anding Hospital
Tianjin, China